Skip to main content

ADDL Begins Limited Testing of Human COVID-19 Samples to Expand Indiana’s Testing Capacity

Angie looks over data on a computer monitor in the lab
Angie Chan, supervisor of the Molecular Diagnostic Section, which performs the Polymerase Chain Reaction (PCR) tests, reviews data from COVID-19 samples. (Purdue University photo/John Underwood)

Purdue University is continuing to lend expertise and resources to help fight the COVID-19 pandemic by increasing Indiana’s testing capacity through the capabilities of the Animal Disease Diagnostic Laboratory (ADDL) at the Purdue University College of Veterinary Medicine. Thanks to a collaborative effort, the ADDL is utilizing its skills and expertise in the detection of pathogens to conduct COVID-19 tests on specimens from partner hospitals with the goal of providing results the same day the samples are received.

The ADDL began COVID-19 testing after obtaining the Clinical Laboratory Improvement Amendments (CLIA) certification required for laboratories performing testing on human samples. The lab was certified in a matter of days after Purdue leaders suggested using the ADDL to conduct tests and address the state’s limited testing capacity and need for resources. State Health Commissioner Kris Box, M.D., FACOG, said in a recent daily briefing with Gov. Eric Holcomb that resources are still limited for COVID-19 testing in Indiana as the number of cases continue to rise.

“The College of Veterinary Medicine has a long history of providing services to protect animal and human health,” said Purdue Veterinary Medicine Dean Willie Reed. “Providing COVID-19 testing is yet another way to support the citizens of Indiana during this unprecedented public health crisis. The project was shepherded by David Broecker, chief innovation and collaboration officer for the Purdue Research Foundation, and involves several partners including the foundation, the Indiana State Department of Health, Parkview Hospital, and the Purdue community.”

Gloved hands disinfect a sample tube with other sample tubes in a stand in the background
When samples are received at the ADDL from hospital partners, the primary transport containers are disinfected and the samples are prepared to be taken to the Molecular Diagnostic Section of the facility for testing. (Purdue University photo/John Underwood)

ADDL Director Kenitra Hendrix says the lab had a unique opportunity to assist with COVID-19 testing in Indiana because of its expertise in providing infectious disease testing and immunity surveillance for animals across the state.  Dr. Hendrix explains the human samples are being tested using a PCR (Polymerase Chain Reaction) testing method that the ADDL uses regularly for animal specimens. “Our plan to help our state in this way does not diminish our capacity for animal testing,” Dr. Hendrix said. “Our primary mission is diagnostic support of animal health and the safety of the food supply, and that will remain our first priority.”

The ADDL team, working with state health authorities, adjusted its intake and sample processing procedures to gain the necessary certification to use the PCR testing capability on human specimens.  “Our team has worked diligently to prepare to perform this testing,” Dr. Hendrix said. “It is rewarding to be able to take on this role in support of the citizens of our state.”

The plan is to expand testing in collaboration with other hospitals, as ADDL testing capacity allows, with all samples sent directly from partner hospitals to the ADDL. To avoid a testing backlog, hospitals interested in working with the ADDL are required to complete the “Partnership Inquiry” form.

The project is a cross-disciplinary, collaborative effort with the Indiana State Department of Health, the Purdue Research Foundation and the Purdue community.  “Indiana continues to increase our capabilities and preparedness for rapidly testing patients to support our front-line health care workers,” Dr. Box said. “We are grateful to Purdue and the ADDL for helping to make testing more available for Hoosiers who are helping others during this pandemic.”

Fort Wayne-based Parkview Health provided clinical expertise on obtaining a CLIA license and setting up the lab for human testing.  “It still takes several days to get results that are sent out to central labs across the country,” said Dr. Michael J. Mirro, chief academic research officer at Parkview Health. “Even the new tests are limited by supply constraints. What Purdue has done is fantastic and shows the ingenuity associated with creative problem solving. Paired with the significant amount of time invested by the Parkview lab team, we believe this will have a positive impact on the state’s testing capacity.”

The ADDL is a Biosafety Level 2 (BSL-2) facility accredited by the American Association of Veterinary Laboratory Diagnosticians (AAVLD). BSL-2 laboratories are used to study moderate-risk infectious agents or toxins.  Dr. Hendrix says that additional partnerships with other hospitals across the state are possible. Click here to view a complete news release about the ADDL COVID-19 testing program.

Writer(s): Purdue News Service and Kevin Doerr | pvmnews@purdue.edu

Recent Stories

“Paws Up” for Jennifer Danaher – brought to you by the PVM Wellness Committee

This week we express our gratitude to Jennifer Danaher, who is department secretary for Veterinary Clinical Sciences.

‘Purdue Pursuits’: A PVM angle on Purdue’s teaching and learning reading groups

Crafting meaningful and engaging course experiences has been at the top of Dielson Vieira’s mind ever since he joined the Purdue University College of Veterinary Medicine’s faculty in 2024. As a clinical assistant professor in the Department of Basic Medical Sciences, Vieira is already adept at applying innovative teaching practices to classroom environments, but that doesn’t stop him from seeking out new ideas, approaches and perspectives — insights he gains through outlets like Purdue’s teaching and learning reading groups.

Top tier biology journal publishes PVM study that unlocks secrets of a drug-resistant fungal pathogen, which causes serious infections in humans

Though the name “Candida auris” is far from a household term, public health experts know it well because the multi-drug-resistant fungal pathogen, which causes serious human infections, has been classified as an urgent threat by the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Threats Report (2019). Dr. Shankar Thangamani, Associate Professor of Microbiology and University Faculty Scholar in the Purdue University College of Veterinary Medicine’s Department of Comparative Pathobiology, is researching C. auris, aided by a 2.4 million grant from the National Institutes of Health (NIH). New research findings, just published in Nature Microbiology, show how C. auris adapts and evades the immune system.

In Print: ‘Translational Research Methods for Tauopathies’

A just-published 300-page volume edited by Jessica Fortin, Purdue assistant professor in the College of Veterinary Medicine’s Department of Basic Medical Sciences, provides a significant new resource for researchers studying a group of neurodegenerative diseases known as tauopathies. “Translational Research Methods for Tauopathies” provides detailed protocols intentionally selected to serve as a basis for research laboratories seeking to further treatments for such debilitating neurodegenerative diseases as Alzheimer’s and chronic traumatic encephalopathy (CTE).

It’s Almost Here!

Though the annual Purdue Veterinary Conference is almost upon us, there’s still time to register and take advantage of this time-honored College of Veterinary Medicine fall tradition that combines excellent continuing education with fun opportunities for reconnecting with colleagues and classmates, networking, and learning about the latest veterinary trends and products. The 2026 Purdue Veterinary Conference takes place September 23–26 on the Purdue University campus. The annual event has something for everyone, from veterinarians to veterinary technicians, faculty, staff and students.